Terminated
PHASE2
INTERVENTIONAL
NCT01388920
Efficacy and Safety Study of Tesamorelin in Chronic Obstructive Pulmonary Disease (COPD) Subjects With Muscle Wasting
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
A significant proportion of COPD subjects experience muscle wasting, which has been associated with increased morbidity, impaired physical functioning, and a poor quality of life. Muscle wasting is associated with reduced muscle strength in COPD subjects. In particular, weakness of peripheral muscles has been reported to play an important role in the reduced functional capacity and impaired exercise performance. The primary objective of this study is to investigate the effect of tesamorelin, in conjunction with exercise training, on lean body mass measured by dual energy x-ray absorptiometry (DXA) scan.
Interventions
Name:
Tesamorelin
Type:
DRUG
Description:
Name:
Placebo
Type:
DRUG
Description:
Primary Outcomes
Measure:
Change From Baseline in Lean Body Mass at 6 Months
TimeFrame:
6 months
Description:
The primary objective of the study was to evaluate the effect of tesamorelin on lean body mass by Dual-energy X-ray absorptiometry (DXA) scan
Trial Information
NCT ID
NCT01388920
Status
Terminated
Study Type
INTERVENTIONAL
Phases
PHASE2
Sponsor
Theratechnologies
Last Updated
December 15, 2025